secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001493152-24-011327
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Provectus Biopharmaceuticals Names Dominic Rodrigues Principal Executive Officer; Bruce Horowitz Resigns
--------------------------------------------------------------------------------

- Bruce Horowitz resigned as COO and Director on March 25, 2024, and entered a termination agreement with a total payment of up to $750,000.
- The termination agreement includes an initial $250,000 payment and a second payment of $258,000 if paid before June 30, 2024, otherwise $500,000.
- Dominic Rodrigues was appointed as chief operations consultant and principal executive officer with a monthly fee of $20,000.
- The company agreed to continue D&O insurance for Horowitz for two years and Horowitz agreed to a five-year standstill.
- The termination agreement includes mutual releases, confidentiality reaffirmation, and non-disparagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315224011327/0001493152-24-011327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315224011327/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer